Overview of experimental vaccines and treatments for Bundibugyo Ebola in DRC outbreak (cnbcafrica.com)

• Three vaccine candidates: rVSV, ChAdOx1, and IAVI single-dose
• Antibody therapies MBP134 and maftivimab under evaluation
• Obeldesivir and remdesivir as antiviral options
• WHO prioritizes experimental countermeasures for Bundibugyo

"A factual overview of experimental vaccines and treatments for the Bundibugyo Ebola strain in the Democratic Republic of Congo outbreak. No approved vaccines or treatments exist for this strain. Most promising candidates include an rVSV-based vaccine from IAVI, a ChAdOx1 vaccine from Oxford/Serum Institute, antibody therapies MBP134 (Mapp Biopharmaceutical) and maftivimab (Regeneron), and antivirals obeldesivir and remdesivir. WHO has prioritized several candidates for emergency use."